ACM
FULC icon

ADAR1 Capital Management’s Fulcrum Therapeutics FULC Stock Holding History

ADAR1 Capital Management’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1M Sell
130,560
-1,123,189
-90% -$10.4M 0.06% 162
2025
Q4 		$14.2M Buy
1,253,749
+912,137
+267% +$9.28M 1.04% 21
2025
Q3 		$3.14M Buy
341,612
+288,263
+540% +$2.09M 0.3% 61
2025
Q2 		$367K Sell
53,349
-437,183
-89% -$2.34M 0.06% 130
2025
Q1 		$1.41M Buy
490,532
+294,284
+150% +$1.08M 0.26% 68
2024
Q4 		$922K Buy
196,248
+140,446
+252% +$518K 0.18% 84
2024
Q3 		$199K Sell
55,802
-312,567
-85% -$2.32M 0.03% 163
2024
Q2 		$2.28M Buy
368,369
+28,544
+8% +$216K 0.43% 40
2024
Q1 		$3.21M Sell
339,825
-297,580
-47% -$2.66M 0.73% 25
2023
Q4 		$4.3M Buy
+637,405
New +$2.83M 1.54% 17

Other funds holding FULC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
FTM
First Turn Management Del Mar, California $895M AUM 261.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

ADAR1 Capital Management's FULC Position: Q1 2026 in Review

ADAR1 Capital Management reduced its Fulcrum Therapeutics (FULC) stake by 90% in Q1 2026, selling an estimated $10.4M and leaving 130,560 shares worth $1M. The position accounts for 0.06% of the portfolio, ranked #162.

ADAR1 Capital Management first reported a position in FULC in Q4 2023 and has held it in 10 quarters since. The position peaked at $14.2M in Q4 2025. 169 funds tracked by Wall St. Rank hold FULC as of Q1 2026.

  • ADAR1 Capital Management held 130,560 shares of Fulcrum Therapeutics worth $1M as of Q1 2026.
  • ADAR1 Capital Management sold 1,123,189 Fulcrum Therapeutics shares in Q1 2026, an estimated $10.4M.
  • Fulcrum Therapeutics made up 0.06% of ADAR1 Capital Management's portfolio in Q1 2026, its #162 holding.
  • ADAR1 Capital Management first reported a position in Fulcrum Therapeutics in Q4 2023 and has held it in 10 quarters since.
  • ADAR1 Capital Management's Fulcrum Therapeutics position peaked at $14.2M in Q4 2025.
  • 169 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2026.

Based on ADAR1 Capital Management's 13F filing for Q1 2026, filed 18 May 2026.